MTBE: the headache of cleaner air. by Medlin, J
The Headache of
Cleaner Air
It began in late 1992-the quiet introduc-
tion of methyl tertiary butyl ether (MTBE)
into unleaded gasoline as a means of reduc-
ing carbon monoxide emissions during the
winter months in targeted U.S. cities.
Shortly afterwards, scattered health com-
plaints, including headaches, dizziness, and
nausea, from residents ofsome areas, along
with reports of more specific health effects
from residents ofFairbanks and Anchorage,
Alaska, began to surface. These reported
health effects led EPA technical experts and
policy-makers to take a closer look at the
MTBE program. The reports also launched
an era ofassiduous research by scientists and
public health officials across the country to
learn more about MTBE's short-term and
long-term, and possibly carcinogenic, health
effects.
A broad spectrum of opinion character-
izes the MTBE debate. The petroleum
industry touts the chemical's benefit as an air
qualityenhancer, while some environmental-
ists and a few scientists deplore it as an
unnecessary additive whose health risks out-
weigh any purported benefits to public
health. Most scientists' views lie somewhere
in between. Rather than enter a fruitless
debate, they continue to ask questions, col-
lect data, and await the results ofstatistically
viable, peer-reviewed research that they hope
will clarifythe MTBE dilemma.
Environmental Benefits
Most scientists, public health
authorities, and even environ-
mental groups agree that, as a
fuel oxygenate, MTBE does
decrease emissions of carbon
monoxide, a toxic gas that
poses a real health risk, espe-
cially to individuals who suf-
f fer from coronary artery dis-
ease. Because carbon monox-
_ ide emissions are highest in
_ cold weather, refiners began
adding 15% MTBE and
other oxygenates including
ethyl tertiary butyl ether
(ETBE), tertiary amylmethyl
ether (TAME), and ethanol
to gasolines used during the
winter months in 39 cities
across the United States to
meet the air quality standards
set in the 1990 CleanAirActAmendments.
MTBE is the most widely used oxy-
genate in the national reformulated gasoline
(RFG) program, an extension ofthe oxyfuels
program. The RFG program debuted in
January ofthis year and has been hailed by
Mary Nichols, the EPA's assistant adminis-
trator for air and radiation, as "the most
importantenvironmental fuels program since
lead was banned from gasoline." The RFG
program, whichwas developedwith coopera-
tion from the oil and chemical industries,
automakers, environmental and citizen
groups, and the EPA, promises to signifi-
cantly reduce emissions ofcarbon monoxide,
volatile organic compounds, nitrous oxides,
and other air toxics. The EPA estimates that
the use ofreformulated gasoline in the nine
target metropolitan areas plus other areas
that opt into the program will reduce smog-
producing emissions by 300,000 tons in
1995 alone-the equivalent of removing 8
millionvehicles from the road.
Gasoline with MTBE has been sold in
the United States since 1979, when the com-
pound was added to fuels as an octane-
enhancer after lead was phased out ofmotor
fuels. According to the MTBE Task Force,
made up ofcompanies that cooperated with
the EPA to initiate MTBE testing, the oxy-
genate is one of the most extensively tested
and best-understood components of gaso-
line. The fuel industry continues to proclaim
the relative safety ofMTBE to.humans and
lauds the chemical's performance in reducing
carbon monoxide levels and ozone-produc-
ing air toxics in most RFG areas. It also
points out that gasoline formulated with or
without MTBE contains carcinogens such as
benzene and that 15% MTBE in gasoline
reduces benzene emissions by 11%.
Despite what MTBE's detractors may
say about the fuel industry's bias, safety
remains a top priority for the industry,
according to John Kneiss, director ofhealth
and product stewardship for the Oxygenated
Fuels Association (OFA). "There is no scien-
tific evidence that exposure to MTBE in its
context is harmful to humans," Kneiss says.
"Our intent is to make gas safer and less pol-
luting. We're supporting additional research
programs to gain greater understanding
about MTBE,"'he adds, referring to the $2
million in additional research the OFA is
underwriting over the next two years. The
OFA has funded $4 million on MTBE
research since 1987, along with millions the
petroleum industryhas spent.
LinkingSymptoms to Exposure
MTBE supporters say the scientific research
confirms that, at concentrations the average
person is exposed to when refueling a vehi-
cle, an amount less than 1 part per million
(ppm), MTBE has a wide safety margin.
Nevertheless, there is still the matter of
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plained ofnausea, dizziness, lightheadedness,
eye, nose, and throat irritation, headaches,
and mostly, the distinct odor. However,
aside from the odor ofMTBE which most
agree is unpleasant, none of these health
symptom complaints has been replicated suc-
cessfullybyscientists in alaboratorysetting.
After complaints from Alaskans during
the winter of 1992-93, the Centers for
Disease Control collaborated with the State
of Alaska, the National Institute for
Occupational Safety and Health (NIOSH),
and the EPA to conduct a two-phase field
epidemiology study in Fairbanks. The study
investigated the possible relationship
between MTBE oxyfuel exposure and symp-
tomatic responses and between MTBE oxy-
fuel exposure and blood levels ofMTBE and
its major metabolite, tertiary butyl alcohol
(TBA).
Survey responses showed an increase in
symptom-reporting rates during phase I,
when MTBE-formulated gasolinewas in use,
over those reported in phase II, when MTBE
was not in use. According to the EPA's
Office ofResearch and Development, causal
relationships between MTBE and symptoms
could not be determined, partly because the
sample size may have been too small to
demonstrate statistical significance andpartly
because there may have been bias in symp-
tom reporting due to extensive negative pub-
licityabout MTBE at the onset ofthe oxyfu-
el season. The study did confirm a relation-
ship between exposure and blood levels of
MTBE and TBA, even at very low concen-
trations ofMTBE.
Following the Alaska studies, the CDC
sponsored two similar studies. One was in
Stamford, Connecticut, an oxyfuels location
where there were no widespread consumer
complaints. The other was in Albany, New
York, chosen for comparison purposes
because the area did not participate in the
oxyfuels program.
The Stamford study yielded no apparent
relationship between symptom prevalence by
occupational category and the median blood
MTBE or TBA concentrations associated
with each category. In fact, the similarity of
responses across job categories in both stud-
ies suggested that the symptoms may not
havebeen due togasoline exposure.
Another epidemiological study soon fol-
lowed, this one conducted by the
Environmental and Occupational Health
Sciences Institute (EOHSI) in New Jersey.
Designed by epidemiologist Sandra N.
Mohr, the study attempted to explore the
relationship between the symptomatic
responses of 237 garage workers from the
New Jersey Departments ofTransportation
and Treasury and exposure to high and low
concentrations of MTBE. Participants were
divided into two groups: one cohort worked
in northern New Jersey and was sampled
during the winter oxyfuel season; the other
group worked in the southern part of the
state and was sampled 10 weeks after oxyfu-
els were phased out in the area. The study,
published in 1994 in Inhalation Toxicology,
found no differences in the reporting of
symptom frequency over a 30-day period
and no differences between the groups across
the work shift. The results led researchers to
conclude that "no untoward health effects
dearly attributable to MTBE exposure could
bedemonstrated."
Though these studies have failed to
directly link adverse health symptoms with
MTBE exposure, at least one scientist
researching MTBE believes the health com-
plaints are legitimate. Myron Mehlman, a
staffscientist atEOHSI, stoutlycontends the
additive is dangerous to human health. He
also remains doubtful about some of the
interpretations and conclusions ofscientists
whose research receives financial support
from the oil industry. "Many reports [have
been] submitted by people who are suffering
as a result ofexposure to MTBE," he says.
"It will be interesting to see how manymore
reports aresubmitted as morepeople become
familiar with the symptoms associated with
MTBE," adds Mehlman, who says he has
conducted two studies that confirm an asso-
ciation betweensymptoms andexposure.
In 1994, Mehlman studied a group of
people in New Jersey who come into daily
contact with presumably higher concentra-
tions of MTBE: members of the Oil,
Chemical & Atomic Workers Union, who
work in refineries blending MTBE with
gasoline. Over a period of several months,
Mehlman recorded symptoms reported by
the workers including neurotoxic, respirato-
ry, and ear-nose-throat symptoms. In one
survey, 91% of the workers reported
headaches, and 50% complained of breath-
ingproblems.
Mehlman also studied more than 200
New Jersey drivers in the winter of 1995
who reported symptoms after exposure to
MTBE. "Eighty percent complained of
headaches, sixty-three percent reported light-
headedness, and forty percent reported an
inability to concentrate," Mehlman says. "A
few complained ofrashes-between five per-
centand tenpercent."
George Lucier, director of the
Environmental Toxicology Program at the
NIEHS, concedes these health symptom
reports can't be ignored altogether, even
though most currently published research
doesn't directly link MTBE to those symp-
toms. "Whenever you look at anecdotal
reports, you have to take them for what they
are and do a careful evaluation," says Lucier.
He also says researchers need to consider
whetherthere maybe asubgroup ofthepop-
ulation that is sensitive to MTBE, or if the
reported symptoms are tied to something
elsealtogether.
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attempted to identify a causal relationship
between MTBE exposure and symptoms in
humans. The first was performed in the
EPA's Health Effects Research Laboratory
(HERL) in Research Triangle Park, North
Carolina. Researchers exposed 40 healthy
male and female subjects (all approximately
25 years old) for 1 hour to 1.39 ppm (5
mg/m3) of pure MTBE-a concentration
that falls within the range
refueling, but is 10 times
surements found in vehi4
minute urban commute.
The study, published
Toxicology in 1994, founc
in symptom reporting due
sure nor increases in object
ocular and nasal inflamma
the subjects' blood-MTBE
to those of occupationally
who reported symptoms
EPA research psychologist
on the study with scientis
the CDC, and the University of North
Carolina, calls the findings "relentlessly non-
significant."
"Bill Cain took our protocol, replicated
it, and found the same results," Prah says,
referring to an inhalation study conducted
by Cain and colleagues at Yale University,
which measured human reactions and phar-
macokinetic responses to low-level MTBE
exposure.




measured during Pharmacokinetic analysis on two subjects
higher than mea- in the HERL study, one male and one
cles during a 30- female, showed a rapid rise ofblood-MTBE
to 8.2 and 14.7 parts per billion, with a rapid ~d in Inhalation decline and clearance half-time of about 36
i neither increases minutes. Levels of TBA increased gradually
> to MTBE expo- to 7-10 parts per billion (ppb) and persisted
tive biomarkers of at half the levels of MTBE for seven hours
tion, even though after the exposure to MTBE. "If there are
levels were similar toxic effects," Prah says, "it's possible that
r exposed workers TBA is responsible, rather than MTBE."
James Prah, an As to why adverse symptoms have been
who collaborated reported by individuals during oxyfuel sea-
;ts from the EPA, sons but haven't been confirmed in the con-
trolled inhalation studies, no one can give a
clear answer. "Maybe it's a combination of
exposures that contributes to the effects, or
there may be people who are more sensitive
to MTBE," suggests Maria Costantini, senior
staff scientist and toxicologist at the Health
Effects Institute in Cambridge, Massa-
chusetts. "The clinical studies have been
done using the pure substance," she explains,
referring to the concentrations of MTBE
used in the HERL and Yale chamber studies.
X "Maybe it's a problem of the mix,"
Costantini says.
Her colleague, HEI President Daniel
Greenbaum, agrees: "There has been relative-
ly little research done on the effects of
MTBE in mixture," Greenbaum says. To
that end, researchers at the EPA's human
studies facility in Chapel Hill, North
Carolina, hope to concoct a "surrogate gaso-
line" from 20-25 of the components found
in gasoline, says Prah. Human subjects in a
controlled environment would be exposed to
a 1% vapor of that mixture, both with and
without MTBE. "Then we'll see if we can
provoke symptoms," Prah explains. "If we
can, we'll group the subjects by symptom
observed."
The hypothesis suggested by both
Costantini and Lucier-that a subpopulation
especially sensitive to MTBE may exist-has
been raised by others in MTBE research.
Nancy Fiedler, along with Mohr and other
researchers at the Robert Wood Johnson
Medical School in Piscataway, New Jersey,
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tion in a study they conducted in 1993.
They administered a symptom questionnaire
to 13 subjects who reported having multiple
chemical sensitivity. Multiple chemical sensi-
tivity sufferers report symptoms and illnesses
in response to low-level exposure to avariety
of chemicals and substances commonly
encountered in the environment. Ques-
tionnaires were also administered to five sub-
jects with chronic fatigue syndrome, as well
as to six healthy control subjects. Symptom
scores from multiple chemical sensitivity
subjects suggested that they indeed experi-
enced greater discomfort in conjunction with
refueling.
The Carcinogenicity Debate
While there is speculation about the factors
that may influence an individual's exposure
to MTBE, there is also much discussion
about the chemical's carcinogenic effects.
According to C.B. Hiremath, a toxicologist
in the EPA's Office ofHealth and Environ-
mental Assessment in Washington, DC, the
EPA classifies MTBE as a "possible carcino-
gen," based on current studies. "We're wait-
ing for more information so we can make a
complete assessment," says Hiremath, who
has been reviewing data on MTBE for two
years.
Two chronic animal cancer bioassays of
MTBE provide the basis for the few conclu-
sions that have been drawn regarding
MTBE's carcinogenicity. Conducted by J.S.
Chun and H.D. Burleigh-Flayer and col-
leagues at Bushy Run Research Center in
Pennsylvania, the bioassays were completed
in 1992. One study exposed groups of rats,
both male and female, to MTBE concentra-
tions of 1,400, 10,800, or 28,800 mg/m3 in
filtered air for six hours a day, five days a
week, for 24 months. Control animals
inhaled filtered aironly.
Researchers observed an increase in rare
kidney tumors in the mid- and high-dose
groups ofmale rats. Exposure-related increas-
es in liver and kidney weights were reported
in females in the mid- and high-exposure
groups. The kidney tumors in male rats
raised the question ofwhether these tumors
were attributable to the accumulation of a
species- and sex-specific protein, alpha-2u-
globulin, which has been associated with a
pattern ofdamage in the kidney tubule cells
ofmale rats. According to EPA reports, little
evidence exists that MTBE causes this pro-
tein to accumulate, though the agency is
awaiting results from ongoingstudies.
The mid- and high-dose groups ofmale
rats also exhibited a statistically significant,
dose-related increase in testicular tumors
compared to controls. But some scientists
question the significance of the tumor
response due to historically high background
incidences of interstitial cell tumors in this
strain ofrat. "Ninety-five percent ofthe con-
trol rats got this tumor," saysJohn Mennear,
a professor of toxicology at the Campbell
University School of Pharmacy who follows
MTBE research as a consultant for ARCO
Chemical Company, the largest producer of
MTBE.
In the second Bushy Run study, groups
ofmale and female mice were exposed to the
same concentrations of MTBE used in the
rat study, for the same exposure durations,
for 18 months. MTBE exposure caused an
increased incidence ofliver tumors in mice at
thehigh dose.
Mennear points out that "it takes a toxic
dose" ofMTBE to elicit a tumor response in
laboratory animals. "Nobody is saying
MTBE is innocuous," he admits. "However,
the concentrations people are exposed to
routinely are not toxic." Mennear and Larry
Andrews, ARCO Chemical's manager of
toxicology and regulatory compliance,
believe that the chronic animal study results
do not imply a risk for humans: "From what
we know about the mechanisms that cause
tumors [in laboratory animals], there is a
large margin of safety for humans," said
Andrews.
Scientists hope new research conducted
by Cesare Maltoni and colleagues at the
Ramazzini Foundation of Oncology and
Environmental Sciences will shed more light
on MTBE's potential as a human carcino-
gen. This study differs from the other chron-
ic animal studies in that MTBE is being
administered to rats by gavage in an olive oil
medium, as opposed to inhalation. Ac-
cording to Mehlman, the study shows
MTBE exposure causes increased levels of
lymphomas and leukemias, which confirms
his view that MTBE is a "poison." North
Carolina's state toxicologist, Ken Rudo,
recently reviewed the Maltoni study. He too,
says the study found leukemias and lym-
phomas, adding that there was a "very, very
clear dose response."
"The study also verified testicular
tumors, but in a different kind of rat with
low background tumor incidence," Rudo
reports. The Maltoni study is weak is some
areas, Rudo claims, because it includes "no
statistics for tumor incidence and no infor-
mation on pathology." In short, he says, "it
doesn't meet the basic criteria for a two-year
bioassay."
Future Research Needs
While opinions on MTBE's carcinogenicity
mayvary amongscientists associatedwith the
issue, most agree that further study is neces-
sary. According to NIEHS's Lucier, the
National Toxicology Program has been
studying the effects ofTBA. This research so
far has shown "the same kind oftumors pro-
duced by MTBE in the EPA-mandated stud-
ies," says Lucier.
Studies currently underway should prove
useful to scientists who must extrapolate the
animal study findings to predict human risk.
Susan Borghoff, a staff scientist at the
Chemical Industry Institute ofToxicology
(CIIT) is developing a physiologically based
pharmacokinetic model for MTBE and TBA
in rats. The model will be used to predict the
blood levels of MTBE in rodents and
enhance the understanding ofthe kinetics of
MTBE and TBA. According to Borghoff,
knowledge ofthe kinetic behavior ofMTBE
and TBA will aid in assessing human risk.
"This is just a first-stage model," says
Borghoff. "Studies have been proposed to
collectthis information in humans."
Other CHT researchers are trying to find
clearer answers to why a number of com-
:t co'i 000(2;'0_09XW-0$'<t';l00''~~it0000!02,
pounds in unleaded gasoline-MTBE
included-cause liver tumors in mice
exposed to high levels. "We're testing the
hypothesis that MTBE in unleaded gasoline
is inducing a liver tumor response through
hormone modulations, specifically estrogen,"
explains Thomas Goldsworthy, a staff scien-
tist at CIIT. The study should yield a dearer
understanding ofthe mechanism that is criti-
cal for the tumor response, as well as the
dosage atwhich the responseoccurs, hesays.
Results of the study, which should be
complete bythe end oftheyear, mayreveal if
tumor response to MTBE is similar to the
tumor response elicited by unleaded gasoline
formulatedwithout MTBE. A previous CHT
study suggested that high-level exposures to
unleadedgasolineproduce an increase in liver
tumors in female mice by interfering with
estrogen hormonefunction.
This finding, according to the CIIT,
seems to suggest two things: that an associa-
tion between unleaded gasoline and increased
incidence ofliver tumors is a high-dose phe-
nomenon thatmaybe unique tofemale mice,
and that such an association wouldn't likely
be observed in humans, due to low exposure
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levels typical for humans. Previous CIHT
research had concluded that the sensitivity of
male rats to kidney tumors stems from the
interaction of unleaded gasoline components
with a kidney protein found in male rats, but
not in humans.
Unleaded gasoline and MTBE have simi-
lar chronic and subchronic effects, says
Goldsworthy. So far, he and his colleagues
have tested unleaded gasoline and MTBE
separately. The next step, Goldsworthy says,
is "to see what happens when you put MTBE
and gasoline together."
Weighing Risks and Benefits
New research should help weigh the risk of
MTBE as a possible carcinogen and the effec-
tiveness of MTBE-blended fuels in reducing
carbon monoxide levels. The question is
whether, in minimizing one risk, is another
risk-however small-being introduced?
"Scientists have to think in these terms of
benefitversus risk," Mennearconcedes.
This kind ofanalysis maylead at least one
oxyfuels state, North Carolina, to petition the
EPA to relieve the state from participating in
the program. The state's Department of
Environment, Health, and Natural Resources
has collected data for two years showing that
the use offuels with MTBE has not reduced
ambient carbon monoxide during the oxyfuel
season below carbon monoxide levels preva-
lent during the remaining months ofthe year
(typically 7-8 ppm based on an 8-hour expo-
sure). "All we were left with was risk, but no
benefit," says Rudo.
Although reductions in carbon monox-
ide levels have been reported in many states,
most notably in the northeast and California,
Rudo would like to see the EPA give states
more latitude in determining the effective-
ness of using oxygenated fuels from the
standpoint ofhealth risks and benefits.
More testing ofthe other oxygenates
_ should be done, according to HEI's
Costantini. "Ethanol has been stud-
ied for ingestion, not inhalation,"
she says. She would like to see a
comparative analysis of the
pharmacokinetics of ethanol
inhalation versus ingestion. She
also believes a comparative study
ofall the oxygenates on their rela-
tive toxicitywould be helpful.
According to Lucier, any risk-
benefit analysis should include an evalu-
ation of alternatives to MTBE. "I think
there is a search for alternatives," he says,
adding a word of caution: "We just don't
want to rush into using another chemical
before it is thoroughly tested."
Lucier says that, in addition to conduct-
ing toxicological evaluations of different
chemicals in the interest ofpublic health, the
National Toxicology Program also provides
regulatory agencies with important data to
strengthen risk assessments. In his role as
chair of the North Carolina Scientific
Advisory Board, Lucier helped formulate an
analysis ofMTBE's effectiveness as a carbon
monoxide reducer versus its human carcino-
genic potential. Extrapolating from the ani-
mal data, Lucier says, "we estimated that the
risk was between zero and one cancer per
100,000 people exposed."
Statistically speaking, MTBE poses avery
low cancer risk to humans, Lucier says,
though that means for 250 million people
exposed over their lifetimes, as many as
2,500 could develop cancer. Which Lucier
points out, shows that "a risk assessment
decision can have tremendous impact," says
Lucier. "The idea is to make gasoline as safe
as possible."
Jennifer Medlin
Volume 102, Supplement 3, September 1994 _K~V eg Environmental Health - Molecular Mechanisms of fSeGtI\~'fS
Metal Toxicity and Carcinogenicity Supplements
Volume 102, Supplement 3, presents the proceedings ofthe Second International Meeting on
Molecular Mechanisms ofMetal Toxicity and Carcinogenicity, heldJanuary 10-17, 1993, in
Madonna di Campiglio, Italy. The main objective ofthe meeting was to provide an opportunity for
scientists in the field ofmetal carcinogenesis and toxicology to discuss and compare their results.
To order your free copy, write:
Supplement Circulation / Environmental Health Perspectives, National Institute of Environmental Health Sciences
PO Box 12233, Research Triangle Park, NC 27709, Fax 919-541-0273